Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02460094 · ClinicalTrials.gov registry record · Phase 1
Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy
A Phase 1 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT02460094 is a Phase 1 study that has completed, run by Biogen. The registered enrollment target is 48 participants.
The verdict
NCT02460094, a Phase 1 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability of multiple ascending intravenous infusions of BMS-986168 and to assess the pharmacokinetics and immunogenicity of BIIB092, and pharmacodynamics of BIIB092 on cerebrospinal fluid (CSF) extracellular tau (eTau) concentrations in participants with Progressive Supranuclear Palsy.
Interventions
- DRUG Placebo
- DRUG BIIB092
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2015-10-02 |
| Est. Completion | 2016-10-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02460094
The ClinicalTrials.gov registry entry for NCT02460094 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02460094 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02460094 about?
NCT02460094 is a clinical study titled "Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy". The purpose of this study is to evaluate the safety and tolerability of multiple ascending intravenous infusions of BMS-986168 and to assess the pharmacokinetics and immunogenicity of BIIB092, and pharmacodynamics of BIIB092 on cerebrospinal fluid (CSF) extracellular tau (eTau) concentrations in par...
What is the current status of trial NCT02460094?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2015-10-02. Estimated completion is 2016-10-19.
What interventions are being tested in trial NCT02460094?
The interventions under investigation include: Placebo (DRUG), BIIB092 (DRUG).
Who is sponsoring clinical trial NCT02460094?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.